• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 21, 2021
Company Drug/Device Medical Condition Status
Asieris Pharmaceuticals APL-1202 in combination with BeiGene's tislelizumab neoadjuvant therapy in patients with muscle-invasive bladder cancer IND approved by the FDA
ImmunityBio Anktiva in combination with standard chemotherapy and Trodelvy (sacituzumab govitecan-hziy) advanced triple-negative breast cancer IND approved by the FDA
Oryzon Therapeutics vafidemstat borderline personality disorder IND approved by the FDA for phase 2b trial
Xilio Therapeutics XTX101 solid tumors IND approved by the FDA
Siranomics STP705 skin squamous-cell carcinoma in situ IND approved by China’s National Medical Product Administration
LivaNova aura6000 System, implantable hypoglossal neurostimulator moderate-to-severe obstructive sleep apnea in adults Investigational Device Exemption approved by the FDA
Quidel Sofia Q rapid antigen test device Emergency Use Authorization granted by the FDA
Blueprint Medicines Ayvakit (avapritinib) advanced systemic mastocytosis (SM), including aggressive SM and SM with an associated hematological neoplasmand mast-cell leukemia approved by the FDA
Eton Pharmaceuticals Rezipres (ephedrine hydrochloride injection) hypotension occurring in the setting of anesthesia approved by the FDA
Gilead Sciences Epclusa (sofosbuvir/velpatasvir) chronic hepatitis C in children as young as three years regardless of HCV genotype or liver disease severity approved by the FDA for new formulation
AVITA Medical Recell System in combination with meshed autografting treatment of all sizes of acute full-thickness thermal burn wounds for both pediatrics and adults approved by the FDA for expanded use
Neo Medical

Osartis
Neo Pedicle Screw System in combination with BonOs Inject cement compromised bone quality in late-stage tumors approved by the FDA
Stratatech StrataGraft deep partial-thickness burns approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing